Equillium (FRA:0FY) Days Sales Outstanding : 45.60 (As of Sep. 2024)

View and export this data going back to 2018. Start your Free Trial

What is Equillium Days Sales Outstanding?

Equillium's average Accounts Receivable for the three months ended in Sep. 2024 was €5.48 Mil. Equillium's Revenue for the three months ended in Sep. 2024 was €10.96 Mil. Hence, Equillium's Days Sales Outstanding for the three months ended in Sep. 2024 was 45.60.

The historical rank and industry rank for Equillium's Days Sales Outstanding or its related term are showing as below:

FRA:0FY' s Days Sales Outstanding Range Over the Past 10 Years
Min: 33.24 Med: 49.49 Max: 65.73
Current: 35.28

During the past 7 years, Equillium's highest Days Sales Outstanding was 65.73. The lowest was 33.24. And the median was 49.49.

FRA:0FY's Days Sales Outstanding is ranked better than
81.9% of 862 companies
in the Biotechnology industry
Industry Median: 70.75 vs FRA:0FY: 35.28

Equillium's Days Sales Outstanding increased from Sep. 2023 (38.36) to Sep. 2024 (45.60).

Equillium Days Sales Outstanding Historical Data

The historical data trend for Equillium's Days Sales Outstanding can be seen below:

* For Operating Data section: All numbers are indicated by the unit behind each term and all currency related amount are in USD.
* For other sections: All numbers are in millions except for per share data, ratio, and percentage. All currency related amount are indicated in the company's associated stock exchange currency.

* Premium members only.

Equillium Days Sales Outstanding Chart

Equillium Annual Data

Trend

Dec17

Dec18

Dec19

Dec20

Dec21

Dec22

Dec23

Days Sales Outstanding

Get a 7-Day Free Trial

65.73

33.67

Equillium Quarterly Data
	Dec19	Mar20	Jun20	Sep20	Dec20	Mar21	Jun21	Sep21	Dec21	Mar22	Jun22	Sep22	Dec22	Mar23	Jun23	Sep23	Dec23	Mar24	Jun24	Sep24
Days Sales Outstanding	Get a 7-Day Free Trial															38.36	37.58	37.44	35.88	45.60

Competitive Comparison of Equillium's Days Sales Outstanding

For the Biotechnology subindustry, Equillium's Days Sales Outstanding, along with its competitors' market caps and Days Sales Outstanding data, can be viewed below:

* Competitive companies are chosen from companies within the same industry, with headquarter located in same country, with closest market capitalization; x-axis shows the market cap, and y-axis shows the term value; the bigger the dot, the larger the market cap. Note that "N/A" values will not show up in the chart.

Equillium's Days Sales Outstanding Distribution in the Biotechnology Industry

For the Biotechnology industry and Healthcare sector, Equillium's Days Sales Outstanding distribution charts can be found below:

* The bar in red indicates where Equillium's Days Sales Outstanding falls into.

Equillium Days Sales Outstanding Calculation

Days Sales Outstanding measures the average number of days that a company takes to collect revenue after a sale has been made. It is a financial ratio that illustrates how well a company's Accounts Receivable are being managed.

Accounts Receivable can be measured by Days Sales Outstanding.

Equillium's Days Sales Outstanding for the fiscal year that ended in Dec. 2023 is calculated as

	Days Sales Outstanding (A: Dec. 2023 )
=	Average Accounts Receivable					/	Revenue	*	Days in Period
=	( (Accounts Receivable (A: Dec. 2022 )	+	Accounts Receivable (A: Dec. 2023 ))	/	count )	/	Revenue (A: Dec. 2023 )	*	Days in Period
=	( (2.679	+	3.425)	/	2 )	/	33.089	*	365
=	3.052					/	33.089	*	365
=	33.67

Equillium's Days Sales Outstanding for the quarter that ended in Sep. 2024 is calculated as:

	Days Sales Outstanding (Q: Sep. 2024 )
=	Average Accounts Receivable					/	Revenue	*	Days in Period
=	( (Accounts Receivable (A: Jun. 2024 )	+	Accounts Receivable (A: Sep. 2024 ))	/	count )	/	Revenue (A: Sep. 2024 )	*	Days in Period
=	( (5.475	+	0)	/	1 )	/	10.957	*	365 / 4
=	5.475					/	10.957	*	365 / 4
=	45.60

Equillium (FRA:0FY) Days Sales Outstanding Explanation

For retailers, when we compare Days Sales Outstanding, it is important to compare the same period in the previous years.

Equillium Days Sales Outstanding Related Terms

Thank you for viewing the detailed overview of Equillium's Days Sales Outstanding provided by GuruFocus.com. Please click on the following links to see related term pages.

Equillium Business Description

Industry

GURUFOCUS.COM » STOCK LIST » Healthcare » Biotechnology » Equillium Inc (FRA:0FY) » Definitions » Days Sales Outstanding

Comparable Companies

Traded in Other Exchanges

EQ:USA 0A4D:UK 0FY:Germany

Address

2223 Avenida De La Playa, Suite 105, La Jolla, CA, USA, 92037

Website

https://www.equilliumbio.com

Equillium Inc is a biotechnology developing therapies to treat severe autoimmune and inflammatory disorders. Its pipeline includes itolizumab, a first-in-class antibody targeting the CD6-ALCAM pathway which plays a key role in the modulation of effector T cells - currently in a Ph 3 study for patients with acute graft-versus-host disease and a Ph 1b study for patients with lupus nephritis. EQ101, a first-in-class cytokine inhibitor that selectively targets IL-2, IL-9, and IL-15 is Ph2-ready and expected to begin enrolling patients in an alopecia areata study in 2H 2022. EQ102, a cytokine inhibitor that selectively targets IL-15 and IL-21, is ready for clinical development and expected to begin enrolling patients in a Ph 1study including patients with celiac disease.

Equillium Headlines

No Headlines